Caffeine and Cataract After Pars Plana Vitrectomy

Cataract Clinical Trial

Official title:

The Effect of Caffeine Consumption on Cataract Formation After Pars Plana Vitrectomy: a Comparative Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06358664
• Other study ID #: Caffeine Vitrectomy
• Status: Recruiting
• Phase: N/A
• Start date: April 1, 2024
• Est. completion date: April 1, 2026

Study information

• Verified date: April 2024
• Source: Vienna Institute for Research in Ocular Surgery
• Contact: Andreas Schlatter, MD
• Phone: +4391021
• Email: office[@]viros.at
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Assessment of cataract development in patients with regular caffeine consumption and those without caffeine consumption after pars plana vitrectomy.

Description:

Vitrectomy is a frequently used surgical procedure in ophthalmology for various indications like retinal detachment repair or macular pucker peeling. Amongst others, accelerated cataract development in phakic patients is a known complication after vitrectomy. A previous study found that especially patients receiving gas tamponade are at increased risk for postoperative cataract development. The assumed mechanism behind this finding is that vitrectomy leads to an increased partial pressure of O2 in the human vitreous - similar to that observed in posterior vitreous detachment - subsequently leading to accelerated lens opacification. Therefore, a possible target of cataract prevention is the inhibition of oxygen radical formation. One known antioxidant agent inhibiting oxygen radical formation is caffeine. For instance, in-vitro studies showed that caffeine consumption can reduce cataract development in ultraviolet (UV)-radiation-exposed rats and human lens epithelial cells through its capability of inhibiting oxygen radical formation. These in-vitro studies support the findings of epidemiological studies that caffeine also in-vivo has the potential to reduce cataractogenesis. Conflating the previous findings of accelerated cataract formation after vitrectomy and the preventive properties of caffeine for cataract development, there may be a benefit for patients regularly consuming caffeine-containing beverages like coffee undergoing vitrectomy regarding postoperative cataract formation. Therefore, the aim of this comparative study is to investigate if patients undergoing small gauge pars plana vitrectomy regularly consuming caffeine have lower postoperative significant cataract formation rates than patients not consuming caffeine.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 74
• Est. completion date: April 1, 2026
• Est. primary completion date: April 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 105 Years

Eligibility

Inclusion Criteria:

• Age 18 or older
• Written informed consent
• No previous cataract surgery in the study eye
• Scheduled small gauge vitrectomy with intraoperative gas tamponade (SF6 or C3F8) due to retinal detachment or macular hole repair
• No regular caffeine consumption (drinking not more than one cup of a caffeine- containing beverage [e.g. coffee, energy drinks] at a maximum of two days per week during the past year)

Exclusion Criteria:

• Intake of systemic or topical corticosteroids within 3 months before study screening
• Increased risk for postoperative cataract development, for example due to ocular trauma in the history
• Severe cataract (LOCS III grading of any cataract form >2) in the study eye at pre- study screening
• Scheduled phacovitrectomy in the study eye
• Participation in any clinical trial three month before study screening
• Ocular surgeries six month before study screening

Related Conditions & MeSH terms

• Cataract

Intervention

Procedure:
• Pars plana vitrectomy
Standard pars plana vitrectomy will be performed

Locations

Country	Name	City	State
Austria	Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital, Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Vienna Institute for Research in Ocular Surgery

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Significant cataract formation at year 1	Frequency of significant cataract formation one year after vitrectomy in study eyes as compared to control eyes	12 months
Secondary	Significant cataract formation at month 6	Frequency of significant cataract formation 6 months after vitrectomy in study eyes as compared to control eyes	12 months
Secondary	Distance corrected visual acuity (DCVA)	DCVA at all study visits in study eyes as compared to control eyes	12 months